Zantac Defendants Support Efforts to Create MDL Docket; Agree with District of New Jersey as Destination



DOCUMENTS
  • Response


WASHINGTON, D.C. –– Defendants named in Zantac personal injury lawsuits have supported recent plaintiff efforts to create a multidistrict litigation docket for the growing number of cases, agreeing with the petitioner’s suggestion that the cases be centralized in the District of New Jersey.

In a Nov. 27 brief filed with the U.S. Judicial Panel on Multidistrict Litigation, defendants Sanofi U.S. Services Inc., Sanofi-Aventis U.S. LLC, Chattem Inc., Boehringer Ingelheim Pharmaceuticals Inc., GlaxoSmithKline LLC, and Pfizer Inc. agreed that the Panel should centralize the litigation in New Jersey before Hon. Freda L. Wolfson.

“All indications are that the Zantac litigation will …






UPCOMING CONFERENCES




HarrisMartin's Webinar Series: Midwest Asbestos Litigation

December 02, 2020 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS



HarrisMartin’s Webinar Series: Surgical Stapler Litigation

January 14, 2021 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS